1056416-78-4

Basic information

• Product Name: N-(3,4-dimethoxybenzyl)-5-(3,5-dimethylphenyl)-2,3’-bipyridine-3-carboxamide
• Synonyms: N-(3,4-dimethoxybenzyl)-5-(3,5-dimethylphenyl)-2,3’-bipyridine-3-carboxamide
• CAS NO: 1056416-78-4
• Molecular Weight: 453.541
• Mol File: 1056416-78-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(3,4-dimethoxybenzyl)-5-(3,5-dimethylphenyl)-2,3’-bipyridine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-dimethoxybenzyl)-5-(3,5-dimethylphenyl)-2,3’-bipyridine-3-carboxamide(1056416-78-4)
• EPA Substance Registry System: N-(3,4-dimethoxybenzyl)-5-(3,5-dimethylphenyl)-2,3’-bipyridine-3-carboxamide(1056416-78-4)

Safety Data

• Hazardous Substances Data: 1056416-78-4(Hazardous Substances Data)

Upstream product

• 1056418-91-7 2,5-dichloro-N-(3,4-dimethoxybenzyl)nicotinamide 
• 78686-83-6 methyl 2-chloro-5-iodo-3-pyridinecarboxylate 
• 1112849-67-8 2-chloro-N-(3,4-dimethoxybenzyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide 
• 329214-79-1 3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1597403-93-4 methyl 2-chloro-5-(3,5-dimethylphenyl)pyridine-3-carboxylate 
• 1056418-53-1 methyl 5-chloro-2,3'-bipyridine-3-carboxylate 
• 1056418-61-1 methyl 5-(3,5-dimethylphenyl)-2,3'-bipyridine-3-carboxylate 
• 59782-85-3 2,5-dichloronicotinic acid 
• 5763-61-1 3,4-dimethoxybenzylamine 
• 1056418-83-7 5-chloro-N-(3,4-dimethoxybenzyl)-2,3'-bipyridine-3-carboxamide 
• 172975-69-8 3,5-dimethylphenyl boronic acid 

Relevant articles and documents

Discovery of 5″-chloro-n-[(5,6-dimethoxypyridin-2- yl)methyl]-2,2':5',3″-Terpyridine-3'-carboxamide (mk-1064): A selective orexin 2 receptor antagonist (2-sora) for the treatment of insomnia

The field of small-molecule orexin antagonist research has evolved rapidly in the last 15 years from the discovery of the orexin peptides to clinical proof-of-concept for the treatment of insomnia. Clinical programs have focused on the development of antagonists that reversibly block the action of endogenous peptides at both the orexin 1 and orexin 2 receptors (OX1R and OX2R), termed dual orexin receptor antagonists (DORAs), affording late-stage development candidates including Merck's suvorexant (new drug application filed 2012). Full characterization of the pharmacology associated with antagonism of either OX1R or OX2R alone has been hampered by the dearth of suitable subtype-selective, orally bioavailable ligands. Herein, we report the development of a selective orexin 2 antagonist (2-SORA) series to afford a potent, orally bioavailable 2-SORA ligand. Several challenging medicinal chemistry issues were identified and overcome during the development of these 2,5-disubstituted nicotinamides, including reversible CYP inhibition, physiochemical properties, P-glycoprotein efflux and bioactivation. This article highlights structural modifications the team utilized to drive compound design, as well as in vivo characterization of our 2-SORA clinical candidate, 5''-chloro-N- [(5,6-dimethoxypyridin-2-yl)methyl] -2,2':5',3''-terpyridine-3'-carboxamide (MK-1064), in mouse, rat, dog, and rhesus sleep models.

BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to bipyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.